recent
studi
shown
gamma
interferon
synerg
innat
ifn
inhibit
herp
simplex
viru
type
replic
vitro
determin
whether
phenomenon
share
herpesvirus
investig
effect
ifn
human
cytomegaloviru
hcmv
replic
found
synerg
innat
ifn
potent
inhibit
hcmv
replic
vitro
pretreat
human
foreskin
fibroblast
hff
alon
inhibit
hcmv
plaqu
format
treatment
inhibit
hcmv
plaqu
format
respect
gener
isobol
plot
verifi
observ
inhibit
hcmv
plaqu
format
replic
hff
synergist
interact
addit
realtim
pcr
analys
hcmv
immedi
earli
ie
gene
reveal
ie
mrna
express
profoundli
decreas
cell
stimul
compar
vehicletr
cell
furthermor
decreas
ie
mrna
express
accompani
decreas
ie
protein
express
demonstr
western
blot
immunofluoresc
conclus
find
suggest
synergist
inhibit
hcmv
replic
mechan
may
involv
regul
ie
gene
express
hypothes
produc
activ
cell
adapt
immun
respons
may
potenti
synerg
endogen
type
ifn
inhibit
hcmv
dissemin
vivo
human
cytomegaloviru
hcmv
ubiquit
betaherpesviru
affect
human
popul
lytic
replic
cycl
hcmv
tempor
regul
cascad
event
initi
viru
bind
host
cell
receptor
upon
entri
cell
viral
dna
transloc
nucleu
express
viral
immedi
earli
ie
earli
late
gene
occur
stepwis
fashion
gener
asymptomat
immunocompet
individu
primari
hcmv
infect
may
caus
infecti
mononucleosi
associ
atherosclerosi
coronari
restenosi
furthermor
hcmv
lead
contributor
congenit
viral
infect
unit
state
europ
caus
cytomegal
inclus
diseas
pneumonia
sever
neurolog
anomali
infect
neonat
like
herpesvirus
hcmv
establish
lifelong
latenc
host
reactiv
occur
caus
sever
fatal
diseas
immunocompromis
individu
cellular
immun
respons
mhc
class
irestrict
tcell
natur
killer
nk
cell
appear
import
factor
control
acut
infect
establish
mainten
viral
latenc
host
howev
mechan
tcell
affect
hcmv
replic
current
undefin
cytotox
tcell
activ
shown
correl
recoveri
hcmv
infect
patient
recent
studi
suggest
immun
cytokin
tumor
necrosi
interferon
ifn
may
direct
inhibitori
effect
hcmv
replic
particular
involv
ifn
mean
curtail
viral
replic
without
cellular
elimin
consist
hypothesi
cytokin
produc
activ
immun
cell
play
direct
role
control
viral
infect
type
ifn
type
ii
ifn
import
compon
host
immun
respons
viral
infect
produc
cell
direct
respons
viral
infect
synthes
almost
exclus
activ
nk
cell
activ
tcell
respons
virusinfect
cell
type
ifn
achiev
antivir
effect
bind
respect
receptor
receptor
result
activ
distinct
relat
janu
kinasesign
transduc
activ
transcript
jakstat
pathway
result
transcript
activ
ifn
target
gene
synthesi
number
protein
interfer
viral
replic
review
although
ifn
effect
inhibitor
virus
vesicular
stomat
viru
encephalomyocard
viru
almost
rna
dna
virus
evolv
mechan
subvert
host
ifn
respons
exampl
hcmv
inhibit
ifnstimul
antivir
immunoregulatori
respons
multipl
step
likewis
herp
simplex
viru
protein
influenza
viru
protein
simian
v
protein
sendai
viru
c
protein
hepat
c
viru
hcv
protein
ebola
viru
protein
shown
block
ifnmedi
respons
infect
cell
howev
sever
studi
shown
virus
normal
resist
effect
type
type
ii
ifn
separ
suscept
ifn
use
combin
exampl
synergist
inhibit
replic
vitro
vivo
addit
recent
report
indic
ifn
use
combin
synergist
antivir
activ
sever
acut
respiratori
syndromeassoci
coronaviru
sarscov
hcv
lassa
viru
present
studi
examin
effect
andor
hcmv
replic
human
foreskin
fibroblast
hff
treatment
hff
separ
inhibit
hcmv
replic
plaqu
reduct
viral
growth
assay
contrast
treatment
inhibit
hcmv
replic
time
greater
achiev
ifn
separ
effect
synergist
natur
mechan
inhibit
may
involv
least
part
regul
ie
gene
express
found
use
combin
type
type
ii
ifn
potent
inhibit
replic
hcmv
vitro
abil
human
inhibit
replic
hcmv
initi
compar
plaqu
reduct
assay
hff
viral
plaqu
format
reduc
fibroblast
treat
iuml
respect
tabl
test
effect
combin
ifntreat
viral
plaqu
format
hff
pretreat
iuml
expect
level
inhibit
achiev
greater
level
inhibit
achiev
ifn
separ
contrast
pretreat
type
ifn
type
ii
ifn
reduc
hcmv
plaqu
effici
respect
tabl
elimin
possibl
effect
mere
result
doubl
total
amount
ifn
per
cultur
test
inhibitori
effect
iuml
ifn
separ
twohundr
iuml
reduc
hcmv
plaqu
format
respect
tabl
level
inhibit
significantli
greater
level
inhibit
achiev
ifn
concentr
iuml
p
suggest
degre
inhibit
observ
attribut
presenc
two
distinct
type
ifn
figur
show
repres
micrograph
hcmv
plaqu
format
ifntreat
hff
consist
result
tabl
hcmv
plaqu
effici
reduc
plaqu
morpholog
smaller
cultur
treat
combin
type
type
ii
ifn
figur
f
phenotyp
also
observ
cultur
treat
alon
figur
although
overal
inhibitori
effect
similar
achiev
hff
page
number
citat
purpos
andor
inhibit
hcmv
plaqu
format
hff
antivir
activ
ifn
hcmv
plaqu
format
assess
gener
doserespons
curv
figur
level
inhibit
achiev
individu
ifn
treatment
concentr
test
contrast
combin
ifn
treatment
achiev
level
inhibit
time
greater
sum
individu
ifn
treatment
determin
enhanc
inhibit
hcmv
observ
hff
treat
type
type
ii
ifn
synergist
employ
synergist
analysi
determin
interact
two
drug
interact
index
initi
calcul
data
gener
dose
respons
experi
figur
assess
synergist
potenti
type
type
ii
ifn
treatment
interact
index
combin
combin
indic
high
degre
synergi
tabl
addit
synergi
confirm
gener
isobologram
concav
isobol
indic
synergi
convex
isobol
indic
antagonist
effect
figur
inhibitori
concentr
determin
dose
respons
experi
ic
isobol
gener
hff
treat
figur
concav
plot
hff
treat
figur
concav
plot
consist
interact
index
determin
tabl
concav
isobol
shown
figur
indic
synergist
relationship
type
ifn
type
ii
ifn
suggest
action
via
distinct
antivir
pathway
character
inhibitori
effect
type
ifn
type
ii
ifn
treatment
fourday
viral
growth
assay
perform
cultur
treat
viral
replic
undetect
lower
limit
detect
day
postinfect
pi
pi
howev
hcmv
replic
averag
titer
pfuml
cultur
respect
figur
vehicletr
cell
replic
averag
titer
pfuml
viral
titer
recov
cell
treat
ifn
separ
reduc
respect
moreov
pi
viral
titer
cell
treat
ifn
separ
equal
viral
titer
recov
vehicletr
cultur
consist
plaqu
reduct
assay
observ
similar
enhanc
inhibitori
effect
hff
treat
combin
type
type
ii
ifn
cultur
treat
iuml
hcmv
replic
detect
begin
pi
yield
titer
lower
limit
detect
assay
compar
hcmv
titer
pfuml
pi
vehicletr
hff
treatment
inhibit
hcmv
replic
hff
averag
respect
compar
ganciclovir
gcv
treat
cell
known
dna
synthesi
inhibitor
hcmv
level
inhibit
achiev
gcvtreat
cultur
compar
cultur
pi
figur
addit
potent
inhibitori
effect
observ
presenc
maintain
pi
figur
inset
indic
effect
mere
delay
viral
replic
hcmv
replic
cycl
multistep
process
begin
viral
attach
entri
host
target
cell
investig
mechan
synergist
inhibit
hcmv
replic
first
examin
effect
ifn
hcmv
entri
hff
cell
treat
vehicl
ifn
hour
h
prior
infect
hcmv
two
h
viral
adsorpt
dna
isol
hcmvinfect
cell
pcr
use
amplifi
bp
fragment
hcmv
ie
gene
figur
treatment
group
pcr
product
yield
increas
function
viral
multipl
infect
moi
moi
test
amount
pcr
product
amplifi
hff
treat
ifn
figur
f
compar
vehicl
c
interact
index
measur
diverg
amount
ifn
observ
produc
inhibitori
effect
combin
b
amount
would
achiev
effect
separ
b
index
less
indic
synergi
index
greater
indic
antagon
index
equal
indic
addit
type
ifn
type
ii
ifn
synergist
inhibit
hcmv
plaqu
format
hff
figur
coamplif
gapdh
bp
pcr
product
serv
intern
load
control
normal
pcr
product
treatment
group
data
shown
amplif
similar
level
pcr
product
hff
suggest
synergist
inhibitori
effect
occur
level
viral
entri
hcmv
gene
express
tempor
regul
ie
gene
first
class
viral
gene
express
hcmv
entri
cell
although
limit
studi
examin
effect
treatment
hcmv
ie
mrna
express
conclus
studi
conflict
like
due
differ
ifn
cell
type
assess
effect
ifn
treatment
ie
gene
express
realtim
pcr
analys
mrna
level
ifntreat
cell
perform
figur
summar
foldrepress
mrna
level
ifntreat
cultur
compar
vehicletr
control
h
pi
ie
mrna
level
hff
treat
individu
either
inhibit
wherea
cell
day
pi
http
treat
mrna
express
inhibit
respect
enhanc
inhibitori
effect
observ
hff
treat
cultur
mrna
express
repress
respect
interestingli
degre
ie
mrna
inhibit
observ
hff
treat
alon
greater
observ
cultur
treat
alon
suggest
type
ifnmedi
inhibit
ie
mrna
express
better
facilit
treatment
rather
ie
protein
express
play
pivot
role
control
subsequ
viral
cellular
gene
express
product
hcmv
infect
inhibitori
effect
level
would
significantli
impair
viral
replic
determin
whether
inhibitori
block
ie
mrna
express
correl
decreas
ie
protein
express
ifntreat
cultur
western
blot
analys
perform
figur
h
pi
slight
reduct
protein
express
observ
hff
treat
moreov
protein
express
decreas
cell
treat
type
type
ii
ifn
greatest
inhibitori
effect
observ
hff
treat
inhibitori
block
ie
protein
express
consist
throughout
h
time
period
data
shown
synergist
inhibit
hcmv
replic
inhibit
ie
gene
express
hypothes
inhibitori
effect
would
maintain
multipl
round
viral
replic
address
question
ie
protein
express
analyz
indirect
immunofluoresc
period
treatment
group
ie
protein
express
detect
earli
h
pi
howev
viral
replic
progress
ie
protein
express
among
ifntreat
group
vari
data
shown
notabl
day
pi
nearli
cell
treat
vehicl
alon
stain
posit
approxim
cell
treat
alon
express
ie
protein
figur
contrast
percentag
cell
express
ie
protein
significantli
reduc
p
treatment
group
receiv
combin
ifn
hff
hff
posit
figur
observ
differ
suggest
cell
treat
type
type
ii
ifn
ie
express
differenti
regul
andor
viral
spread
sever
hinder
immun
respons
viral
infect
respons
prevent
viral
dissemin
uncontrol
replic
within
host
follow
viral
infect
type
ifn
secret
infect
cell
function
induc
antivir
state
neighbor
uninfect
cell
infiltr
immun
cell
nk
cell
macrophag
secret
numer
chemokin
cytokin
contribut
overal
antivir
respons
upon
activ
adapt
immun
respons
tcell
add
milieu
immun
cytokin
present
site
viral
infect
secret
addit
cytokin
includ
although
sever
studi
examin
effect
proinflammatori
cytokin
hcmv
replic
vitro
studi
limit
examin
effect
one
type
cytokin
viral
replic
rather
examin
cytokin
combin
support
latter
recent
studi
shown
type
type
ii
ifn
function
synergi
inhibit
rna
dna
virus
includ
hcv
sarscov
lassa
viru
studi
may
accur
repres
vivo
inflammatori
respons
result
viral
infect
result
present
herein
consist
hypothesi
establish
type
ifn
type
ii
ifn
synergist
inhibit
replic
hcmv
present
studi
demonstr
combin
treatment
type
type
ii
ifn
render
cell
nonpermiss
hcmv
replic
vitro
inhibitori
effect
synergist
natur
tabl
figur
degre
inhibit
match
increas
concentr
individu
ifn
tabl
figur
result
indic
observ
ifninduc
antivir
effect
direct
result
presenc
two
distinct
type
ifn
moreov
inhibit
hcmv
replic
cell
treat
observ
hff
embryon
lung
fibroblast
data
shown
infect
either
townegfp
see
method
anoth
laboratori
strain
data
shown
mechan
hcmv
replic
inhibit
remain
unclear
type
type
ii
ifn
may
synerg
act
one
differ
stage
hcmv
lytic
cycl
viral
attach
viral
entri
ie
gene
express
earli
gene
express
dna
replic
late
gene
express
viru
assembl
viral
egress
matur
address
question
attach
entri
pcr
use
amplifi
viral
dna
ifntreat
vehicletr
cultur
shortli
infect
previous
observ
ifn
treatment
prevent
viral
entri
cell
indic
equal
pcr
product
yield
treatment
group
figur
data
indic
ifn
exert
inhibitori
effect
step
viral
attach
entri
previous
yamamoto
et
al
demonstr
treatment
cell
potent
inhibit
hcmv
replic
howev
studi
neither
determin
whether
effect
synergist
identifi
mechan
inhibit
howev
author
suggest
ifnmedi
inhibit
hcmv
might
occur
prior
earli
gene
express
similarli
cours
experi
util
townegfp
strain
notic
cell
express
green
fluoresc
protein
gfp
treat
togeth
data
shown
recombin
town
strain
gfp
express
driven
earli
promot
lack
gfpposit
cell
group
suggest
us
synergist
antivir
activ
mediat
type
type
ii
ifn
occur
stage
prior
earli
gene
express
previou
studi
shown
type
type
ii
ifn
treatment
inhibit
hcmv
ie
mrna
express
andor
hcmv
ie
protein
express
use
realtim
pcr
show
treatment
inhibit
ie
mrna
express
fold
h
pi
combin
treatment
inhibit
ie
mrna
express
fold
note
inhibitori
effect
abolish
h
pi
data
shown
suggest
ie
mrna
express
delay
ifn
treatment
observ
decreas
viral
ie
mrna
express
accompani
decreas
ie
protein
express
viral
ie
protein
express
reduc
hff
treat
type
type
ii
ifn
figur
furthermor
immunofluoresc
microscopi
ie
protein
express
reveal
nearli
vehicleand
individu
ifntreat
cell
express
pi
compar
cell
treat
respect
figur
appear
although
individu
ifn
treatment
result
margin
inhibit
ie
express
earli
infect
effect
maintain
demonstr
high
viral
titer
pi
figur
increas
ie
protein
express
pi
figur
addit
hcmv
cytopath
effect
character
enlarg
cell
contain
intranuclear
cytoplasm
inclus
increas
time
vehicleand
individu
ifntreat
group
morpholog
unchang
cell
treat
data
shown
collect
data
suggest
synergist
inhibit
hcmv
replic
may
involv
least
part
regul
ie
gene
express
signific
inhibitori
block
level
evid
phenotyp
mutant
virus
consid
greav
colleagu
demonstr
hcmv
mutant
exhibit
diminish
replic
effici
reduc
abil
form
plaqu
well
defect
earli
gene
express
interestingli
presenc
type
type
ii
ifn
hcmv
show
similar
replic
gene
express
defect
although
data
suggest
ie
gene
regul
contribut
synergist
inhibit
hcmv
replic
mechan
may
also
affect
dramat
respons
accordingli
decreas
ie
protein
level
exce
ie
mrna
level
respons
suggest
addit
regul
level
translat
posttransl
process
andor
protein
stabil
may
involv
delin
put
regulatori
mechan
contribut
synergist
inhibit
hcmv
replic
focu
ongo
studi
type
ifn
type
ii
ifn
activ
distinct
relat
jakstat
signal
cascad
result
transcript
sever
hundr
ifnstimul
gene
although
similar
gene
activ
three
ifn
der
et
al
identifi
numer
gene
differenti
regul
particular
stimul
induc
twice
mani
gene
compar
differenti
regul
ifninduc
gene
may
explain
part
fact
level
inhibit
observ
hff
treat
consist
greater
observ
cell
treat
although
bind
receptor
similarli
compar
individu
consist
inhibit
hcmv
replic
ie
gene
express
level
greater
therefor
better
understand
cellular
factor
involv
synergist
inhibit
hcmv
profil
ifnstimul
gene
present
cell
treat
type
type
ii
ifn
examin
guidotti
chisari
report
model
noncytolyt
control
viral
infect
innat
adapt
immun
respons
cytokin
implic
direct
role
viral
clearanc
demonstr
togeth
innat
ifn
synergist
inhibit
replic
hcmv
vitro
hypothes
produc
activ
cell
adapt
immun
respons
may
potenti
synerg
endogen
type
ifn
inhibit
hcmv
dissemin
facilit
establish
andor
mainten
latenc
host
studi
requir
evalu
role
type
type
ii
ifn
regul
hcmv
replic
hff
virom
minneapoli
mn
maintain
minim
essenti
medium
mem
supplement
fetal
bovin
serum
penicillin
g
uml
streptomycin
mgml
mm
lglutamin
mm
sodium
pyruv
nonessenti
amino
acid
co
hcmv
strain
rvdlmwtgfp
propag
hff
previous
describ
rvdlmwtgfp
refer
townegfp
throughout
manuscript
recombin
hcmv
strain
town
express
gfp
control
earli
promot
viru
kindli
donat
mark
f
stinski
previous
describ
plaqu
reduct
assay
vehicleand
ifntreat
hff
infect
fix
inoculum
townegfp
h
adsorpt
inoculum
remov
medium
contain
methylcellulos
fisher
scientif
houston
tx
respect
ifn
ad
cell
plaqu
number
determin
later
fluoresc
microscopi
nikon
invert
epifluoresc
microscop
nikon
usa
lewisvil
tx
viral
replic
assay
vehicleand
ifntreat
hff
infect
townegfp
moi
h
adsorpt
inoculum
remov
monolay
wash
twice
pb
fresh
ifncontain
medium
return
well
gcvtreat
group
gcv
sigma
st
loui
mo
ad
cultur
medium
immedi
follow
infect
one
pi
cell
medium
harvest
titer
infecti
viru
determin
microtit
plaqu
assay
hff
determin
degre
antivir
interact
type
type
ii
ifn
interact
index
calcul
use
inequ
b
b
b
b
b
ifn
concentr
need
jointli
produc
effect
consider
b
ifn
concentr
capabl
produc
effect
term
isoeffect
dose
interact
index
valu
less
indic
synerg
interact
index
valu
greater
indic
antagon
interact
index
valu
equal
indic
addit
isobologram
also
gener
geometr
assess
degre
antivir
interact
type
type
ii
ifn
previous
describ
use
guidelin
describ
berenbaum
isobol
gener
ic
valu
variou
concentr
presenc
variou
concentr
concav
isobol
indic
synergi
convex
isobol
indic
antagonist
effect
figur
synergi
experi
hcmv
plaqu
reduct
assay
conduct
describ
vehicleand
ifntreat
hff
inocul
townegfp
moi
h
adsorpt
inoculi
remov
cell
wash
twice
pb
subsequ
treat
trypsin
minut
ensur
releas
viru
adher
enter
cell
cell
pellet
wash
twice
pb
remov
trypsin
nonadh
viru
dna
isol
sampl
standard
phenol
chloroform
dna
extract
procedur
hcmvspecif
oligonucleotid
primer
use
amplifi
bp
product
correspond
exon
hcmv
ie
gene
describ
previous
pcr
product
resolv
agaros
gel
imag
use
alpha
innotech
gel
document
system
alpha
innotech
corp
san
leandro
ca
